In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, ...

September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.